Who are ALK-001 oral capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alk-001-oral-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

ALK-001 oral capsule — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ALK-001 oral capsule (ALK-001 oral capsule) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Visual cycle modulator. Area: Ophthalmology.

phase 3 Visual cycle modulator Visual cycle (retinoid metabolism pathway) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

ALK-001 oral capsule (ALK-001 oral capsule) — Alkeus Pharmaceuticals, Inc.. ALK-001 is a retinoid that reduces toxic bisretinoid accumulation in the retina by inhibiting the visual cycle.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ALK-001 oral capsule TARGET	ALK-001 oral capsule	Alkeus Pharmaceuticals, Inc.	phase 3	Visual cycle modulator	Visual cycle (retinoid metabolism pathway)
PA	PA	Fovea Pharmaceuticals SA	marketed	Visual cycle modulator / Retinoid analog

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Visual cycle modulator class)

Alkeus Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALK-001 oral capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/alk-001-oral-capsule. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab